Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

NCT06865365 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests whether adding the medication liraglutide to standard dietary measures helps adolescents with obesity lose more weight before surgery compared to dietary measures alone.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 72 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-05 · est. completion 2028-02

What this study is testing ClinicalTrials.gov NCT06865365 ↗

Description as written by the study sponsor.

The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet. The investigator is researching how much additional preoperative weight loss is possible with the drug admitted preoperatively.

Treatments tested

Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions Drug

Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
Dietologic measures and lifestyle optimization for weight loss Behavioral

all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.

Main thing measured	% total weight loss
Sponsor	Medical University of Vienna
Conditions studied	Obesity, Adolescent
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06865365 ↗